Iovance Biotherapeutics, Inc. 2026 Q3 - Results - Earnings Call Presentation
Barclays Maintains Overweight on Iovance Biotherapeutics, Raises Price Target to $19
Citizens Maintains Market Outperform on Iovance Biotherapeutics, Raises Price Target to $12
Iovance Biotherapeutics Inc (IOVA) (Q3 2026) Earnings Call Highlights: Record $122 Million ...
Iovance Q3 Earnings: Why I'm Reiterating My Buy Call Despite Market Reaction
Iovance Biotherapeutics (IOVA) Lifileucel Wins Fast Track After Strong Sarcoma Trial Data
Loading...